Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.

Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May t
Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May to June 2024, adults without diabetes who had a body mass index of 28 or greater or 24 or greater with at least 1 weight-related comorbidity were enrolled, with final follow-up on June 20, 2025. Participants were randomized to receive once-weekly subcutaneous ribupatide (target doses of 2 mg, 4 mg, or 6 mg) or matching placebo for 48 weeks, with dose escalation for up to 20 weeks and concomitant lifestyle intervention. The primary outcome was change in body weight from baseline to week 48, including percent change in body weight and the percentage of participants achieving at least 5% body weight reduction, analyzed under the treatment policy estimand. Among 567 randomized participants (309 [54.5%] female; mean [SD] age was 34.4 [8.4] years, body weight was 93.0 [17.3] kg, and body mass index was 33.3 [4.5]), 514 (90.7%) completed the 48-week treatment period. Least-squares mean percentage changes in body weight at week 48 were -10.7%, -16.4%, and -17.7% with ribupatide 2, 4, and 6 mg, respectively, vs -1.4% with placebo. At week 48, the placebo-adjusted differences in percentage change in body weight were -9.3 (95% CI, -11.4 to -7.3) percentage points with ribupatide 2 mg, -15.0 (95% CI, -17.1 to -12.9) percentage points with ribupatide 4 mg, and -16.3 (95% CI, -18.4 to -14.2) percentage points with ribupatide 6 mg (P < .001 for all). For at least 5% body weight reduction at week 48, the multiply imputed response rates were 68.1% (95% CI, 59.9% to 75.3%) for ribupatide 2 mg (97 of 142), 88.0% (95% CI, 81.3% to 92.6%) for ribupatide 4 mg (124 of 141), 85.7% (95% CI, 78.6% to 90.7%) with ribupatide 6 mg (121 of 141), and 16.0% (95% CI, 10.8% to 23.1%) with placebo (23 of 143). Placebo-adjusted differences for ribupatide 2, 4, and 6 mg were 52.0 (95% CI, 42.2 to 61.9), 72.0 (95% CI, 63.7 to 80.2), and 69.7 (95% CI, 61.1 to 78.3) percentage points, respectively (all P < .001). The most frequent treatment-emergent adverse events with ribupatide were gastrointestinal events, occurring in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with 23.1% receiving placebo; most were mild to moderate in severity and few participants (0.7%) permanently discontinued study treatment because of adverse events. Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings. ClinicalTrials.gov Identifier: NCT06396429.




